Outcome MeasureOther

BPRS

Brief Psychiatric Rating Scale

2 Papers in Blossom

Clinical Thresholds

Minimal symptoms

Mild

Moderate

Severe

18126

Minimal symptoms

Score 18–30

Mild

Score 31–40

Moderate

Score 41–52

Severe

Score 53–126

Outcome Data Across Studies

Reported results for BPRS across 2 studies with quantitative data.

Outcome data across 8 study arm–timepoint observations
					SD
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer 2011Secondary	Psilocybin(experimental)	0	12	—	—	—
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer 2011Secondary	Active Niacin Placebo(active_comparator)	0	12	—	—	—
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression 2023Safety	Dose A(experimental)	0	—	—	—	—
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression 2023Safety	Dose A(experimental)	7	—	—	—	—
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression 2023Safety	Dose B(experimental)	0	—	—	—	—
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression 2023Safety	Dose B(experimental)	7	—	—	—	—
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression 2023Safety	Individualised(experimental)	0	—	—	—	—
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression 2023Safety	Individualised(experimental)	7	—	—	—	—

Papers Using BPRS

Open Accessindividual

A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

In a Phase 1/2 trial of 16 adults with treatment‑resistant depression, inhaled 5‑MeO‑DMT (GH001) was evaluated as single doses (12 mg, 18 mg) and as an individualized regimen of up to three ascending doses in one day. GH001 was well tolerated and produced ultra‑rapid antidepressant effects, with remission at day 7 in 7/8 (87.5%) patients in the individualized dosing group, markedly higher than the single‑dose arms.

Published: June 20, 2023
Journal: Frontiers in Psychiatry
Authors: Reckweg, J., van Leeuwen, C., Theunissen, E. L., Mason, N. L., Paci, R., Terwey, T. H., Ramaekers, J. G.

Open Accessindividual

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

This is the first (modern) double-blind placebo-controlled study (n=12) of psilocybin (14mg/70kg) for the treatment of (end-of-life) anxiety (and depression) related to cancer. Treatment led to a significant reduction in anxiety symptoms up to three months after treatment and improvements in depressive symptoms reached significance after six months.

Published: January 3, 2011
Journal: JAMA Psychiatry
Authors: Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., Greer, G. R.

Quick Facts

Full Name: Brief Psychiatric Rating Scale
Domain: Other
Papers Indexed: 2
Score Range: 18–126
Interpretation: Lower = better
Unit: points

All Measures